Gemst: a taylor-made combination that reverts neuroanatomical changes in stroke

Submitted: 14 March 2017
Accepted: 12 May 2017
Published: 25 May 2017
Abstract Views: 1320
PDF: 525
HTML: 189
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In a single transient middle cerebral artery occlusion model of stroke and using immunohistochemical techniques, the effects of a new therapeutic approach named Gemst (a member of the Poly-L-Lysine innovative therapies) have been studied in the rat brain. The expression of inflammatory (CD45, CD11b), oxidative (NO-tryptophan, NO2-tyrosine) and indoleamine 2, 3-dioxygenase pathway (kynurenic acid, 3-hydroxy anthranilic acid) markers has been evaluated in early and late phases of stroke. For this purpose, we have developed eight highly specific monoclonal antibodies directed against some of these markers. In the early phase (3 and 5 days of the stroke, we observed no effect of Gemst treatment (7.5 mg/day, subcutaneously for 3, 5 days). In the late phase (21 days) of stroke and exclusively in the ipsilateral side of non-treated animals an overexpression of kynurenic acid, 3-hydroxy anthranilic acid, CD45, CD11b, GFAP and ionized calcium-binding adapter molecule 1 (IBA-1) was found. In treated animals, the overexpression of the four former markers was completely abolished whereas the overexpression of the two latter ones was decreased down to normal levels. Gemst reversed the pathological conditions of stroke to normal situations. Gemst exerts a multifunctional action: down-regulates the indoleamine 2, 3-dioxygenase pathway and abolishes brain infiltration, microglial activation and gliosis. Moreover, Gemst has no effect on the expression of doublecortin, a protein involved in neuronal migration. Gemst could be a new drug for the treatment of stroke since it reverses the pathological findings of stroke and normalizes brain tissue conditions following the ischemic insult.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

GEMAC S.A. Laboratories (Saint Jean d’Illac, France), IDRPHT (Talence, European Union FP7 Collaborative Grant TargetBraIn (number 279017)
Arturo Mangas, Gemacbio
Research Department Chief
Antibodies Department Manager
Javier Yajeya, University of Salamanca, School of Medicine, Department of Physiology
School of Medicine, Department of Physiology
Michel Geffard, Gemacbio - Institut pour le Développement de la Recherche en Pathologie Humaine et Thérapeutique (IDRPHT)

CSO

How to Cite

Mangas, A., Yajeya, J., González, N., Ruiz, I., Pernía, M., Geffard, M., & Coveñas, R. (2017). Gemst: a taylor-made combination that reverts neuroanatomical changes in stroke. European Journal of Histochemistry, 61(2). https://doi.org/10.4081/ejh.2017.2790

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.